Neko Health AB appears in FDA’s 510(k) premarket notification database as the applicant for Echo-2, filed under product code QOK with a decision date of September 22, 2026. The filing record lists a Danderyd, Sweden address and a cardiovascular advisory committee review. Separately, the manufacturer’s own website describes a preventive health scan built around proprietary devices and clinician review, with published pricing for the United States and Sweden. The two bodies of documentation describe related but distinct things: a regulatory clearance for one device, and a commercial scan service that the company says uses multiple devices. [1][3][7]
The Echo-2 clearance and its documented scope
FDA’s 510(k) record for K254240 identifies Neko Health AB as applicant and Echo-2 as the device name, with a decision code of SESE and a decision description of Substantially Equivalent dated September 22, 2026. The record lists product code QOK, device class 2, regulation number 870.2786 and a cardiovascular advisory committee. The associated openFDA device name is hardware and software for optical camera-based measurement of heart rate and respiratory rate. The submission was received December 29, 2025, and the clearance type is listed as Traditional with a Summary statement. [1]
The 510(k) summary document dated September 22, 2026 describes a laser vibrometer that detects vibrations of the skin surface using doppler principles and displays acceleration of the skin. That document is the FDA-published summary accompanying the clearance, and it is the appropriate place to look for the technical description of what was reviewed. The database entry alone does not establish clinical performance, and no outcome measures are reported in the cited records. [4]
Published device families beyond Echo
Neko Health’s technology page states that since 2018 the company has built proprietary medical devices in-house, bringing imaging, optical sensing and precision technology into one system. It names three device families: Derma for skin and body imaging, Spectrum for tissue imaging, and Echo for cardiovascular assessment. The page also refers to spatial data analyzed to estimate body volume and composition and to capturing thousands of images in a flash. These are the manufacturer’s descriptions of its own products, not FDA findings. [3]
The company’s about page states that it was established in 2018 in Stockholm, Sweden, and that it began inventing technologies for preventive health, including the Neko Spectrum, shown there as a prototype. That page frames the work around proprietary devices, real-time data science and a clinical model oriented toward healthy people rather than only the sick. The prototype designation is the company’s own wording and should not be read as a statement of commercial availability. [5]
The scan service and its stated components
The company’s scan page describes a one-hour visit in which data is captured across skin, heart, blood and metabolic health, followed by a clinician helping the person understand the results. The same page lists the United States price as $499 and notes HSA/FSA eligibility, with a waitlist for joining. The Swedish-language version of the site lists 2,750 kr for the same one-hour scan. Pricing and waitlist status are the manufacturer’s published commercial information. [7][5]
A separate scan-facts page states that doctors perform all medical assessments and lists the tests and equipment used in the United States, including brachial blood pressure on the left and right sides measured with a sphygmomanometer and ankle blood pressure on both sides. It also lists an automated wireless ankle-brachial index system with simultaneous measurement among the medical devices used. The page attributes listed devices to Neko Health AB and references EU MDR and EU IVDR classifications for some items. [6]
What the filing record does and does not establish
The linked collection for this company contains one 510(k) record, K254240, with a decision of SESE. That count reflects the filings retrieved as of the snapshot date and is not a measure of total company portfolio, sales or safety performance. The broader FDA query covering decision dates from September 21 to December 31, 2026 returned 75 results in total, a figure that describes the query window rather than Neko Health’s activity. [1][8]
The FDA records identify Neko Health AB as the legal applicant on K254240 and give a filing address in Danderyd, Sweden. They do not establish ownership, parent companies, brand relationships or headquarters beyond what the company itself publishes. The company’s own pages state Stockholm, Sweden as its founding location. No verified parent or brand relationship appears in the cited documents, so none is asserted here. [1][5]
